Prognostic Value of "CD200" in Hematological Malignancies. Hematological Malignancies Comprise a Group of Malignant Clonal Disorders Arising From the Hematopoietic Tissues , Including Leukemia , Multiple Myeloma , and They Have a High Morbidity and Mortality

Study Purpose

Prognostic value of 'CD200' in hematological malignancies Hematological malignancies comprise a group of malignant clonal disorders arising from the hematopoietic tissues , including leukemia , multiple myeloma , and lymphoma , and they have a high morbidity and mortality

Recruitment Criteria

Accepts Healthy Volunteers Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms	Unknown
Study Type An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes. An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes. Searching Both is inclusive of interventional and observational studies.	Observational [Patient Registry]
Eligible Ages	1 Year - 60 Years
Gender	All

More Inclusion & Exclusion Criteria

Inclusion Criteria:

- Newly diagnosed cases of hematological malignancis.

Exclusion Criteria:

- Known cases of hematological malignancies and on treatment.

Trial Details

Trial ID: This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.	NCT06258629
Phase Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans. Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data. Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs. Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.
Lead Sponsor The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.	Sohag University
Principal Investigator The person who is responsible for the scientific and technical direction of the entire clinical study.	N/A
Principal Investigator Affiliation	N/A
Agency Class Category of organization(s) involved as sponsor (and collaborator) supporting the trial.	Other
Overall Status	Not yet recruiting
Countries
Conditions The disease, disorder, syndrome, illness, or injury that is being studied.	Hematological Malignancies

Arms & Interventions

Arms

: control group

Age and sex matched healthy control individuals

: Case group

Available number of patients with newly diagnosed as hematological malignancy

: Case group after 6 months

Available number of patients with newly diagnosed as hematological malignancy after 6 months of starting treatment.

Interventions

Diagnostic Test: - Flowcytometry on bone marrow aspiration

Flowcytometry on bone marrow aspiration

Contact Information

This trial has no sites locations listed at this time. If you are interested in learning more, you can contact the trial's primary contact:

Reem ya Hashim, resident

reem011091@med.sohag.edu.eg

01285481488

For additional contact information, you can also visit the trial on clinicaltrials.gov.

Clinical Trial Finder